Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis

• Published in: PloS one Vol. 19; no. 5; p. e0303337
• Main Authors: Aung, Tin May, Ngamjarus, Chetta, Proungvitaya, Tanakorn, Saengboonmee, Charupong, Proungvitaya, Siriporn
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 17.05.2024; Public Library of Science (PLoS)
• Subjects: 2-Methylisoborneol; Bias; Biological markers; Biology and Life Sciences; Biomarkers; Biomarkers, Tumor - metabolism; Brain research; Brain tumors; Cyclin A; Cyclin-dependent kinase inhibitor p21; DNA topoisomerase (ATP-hydrolysing); DNA Topoisomerases, Type II - metabolism; Growth factors; Humans; Immunohistochemistry; Ki-67 Antigen - metabolism; Liver cancer; Medical prognosis; Medical research; Medicine and Health Sciences; Medicine, Experimental; Meningeal Neoplasms - diagnosis; Meningeal Neoplasms - metabolism; Meningeal Neoplasms - mortality; Meningeal Neoplasms - pathology; Meningioma; Meningioma - diagnosis; Meningioma - metabolism; Meningioma - mortality; Meningioma - pathology; Meta-analysis; Physical Sciences; Poly-ADP-Ribose Binding Proteins; Progesterone; Prognosis; Research and Analysis Methods; Risk assessment; Statistical analysis; Survival; Systematic review; Tumor proteins; Tumor Suppressor Protein p53 - metabolism; Tumors; Vascular endothelial growth factor; Vascular Endothelial Growth Factor A - metabolism
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0303337

Meningioma is the most common primary brain tumor and many studies have evaluated numerous biomarkers for their prognostic value, often with inconsistent results. Currently, no reliable biomarkers are available to predict the survival, recurrence, and progression of meningioma patients in clinical practice. This study aims to evaluate the prognostic value of immunohistochemistry-based (IHC) biomarkers of meningioma patients. A systematic literature search was conducted up to November 2023 on PubMed, CENTRAL, CINAHL Plus, and Scopus databases. Two authors independently reviewed the identified relevant studies, extracted data, and assessed the risk of bias of the studies included. Meta-analyses were performed with the hazard ratio (HR) and 95% confidence interval (CI) of overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS). The risk of bias in the included studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool. A total of 100 studies with 16,745 patients were included in this review. As the promising markers to predict OS of meningioma patients, Ki-67/MIB-1 (HR = 1.03, 95%CI 1.02 to 1.05) was identified to associate with poor prognosis of the patients. Overexpression of cyclin A (HR = 4.91, 95%CI 1.38 to 17.44), topoisomerase II α (TOP2A) (HR = 4.90, 95%CI 2.96 to 8.12), p53 (HR = 2.40, 95%CI 1.73 to 3.34), vascular endothelial growth factor (VEGF) (HR = 1.61, 95%CI 1.36 to 1.90), and Ki-67 (HR = 1.33, 95%CI 1.21 to 1.46), were identified also as unfavorable prognostic biomarkers for poor RFS of meningioma patients. Conversely, positive progesterone receptor (PR) and p21 staining were associated with longer RFS and are considered biomarkers of favorable prognosis of meningioma patients (HR = 0.60, 95% CI 0.41 to 0.88 and HR = 1.89, 95%CI 1.11 to 3.20). Additionally, high expression of Ki-67 was identified as a prognosis biomarker for poor PFS of meningioma patients (HR = 1.02, 95%CI 1.00 to 1.04). Although only in single studies, KPNA2, CDK6, Cox-2, MCM7 and PCNA are proposed as additional markers with high expression that are related with poor prognosis of meningioma patients. In conclusion, the results of the meta-analysis demonstrated that PR, cyclin A, TOP2A, p21, p53, VEGF and Ki-67 are either positively or negatively associated with survival of meningioma patients and might be useful biomarkers to assess the prognosis.